[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352650-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352650-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","repurposing-hetrombopag-for-multiple-myeloma-by-targeting-pnpo-a-celastrol-inspired-approach","Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO - A Celastrol-Inspired Approach","","Multiple myeloma (MM) is driven by plasma-cell dysfunction that elevates reactive oxygen species (ROS) and promotes disease progression. Celastrol, a Traditional Chinese Medicine compound, can intensify ROS to toxic levels and induce apoptosis, with pyridoxine-5′-phosphate oxidase (PNPO) identified as a celastrol target. PNPO is highly expressed in cancers including MM; higher levels correlate with increased proliferation and osteoclast differentiation via exosomes. Structure-based virtual screening targeting PNPO residues (R95 and K117) identified hetrombopag as a PNPO inhibitor, suppressing MM proliferation and osteoclast differentiation, with preliminary clinical data suggesting prolonged survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/repurposing-hetrombopag-for-multiple-myeloma-by-targeting-pnpo-a-celastrol-inspired-approach/352650/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/repurposing-hetrombopag-for-multiple-myeloma-by-targeting-pnpo-a-celastrol-inspired-approach/352650.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is ROS elevated in multiple myeloma cells, and how does it affect disease progression?","Question",{"text":63,"@type":64},"MM plasma cells produce excessive immunoglobulins that raise ROS. The elevated ROS further accelerates proliferation through PI3K/MAPK signalling and promotes osteoclast differentiation via RANKL, contributing to bone damage and reduced survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does PNPO play in MM according to the study?",{"text":68,"@type":64},"PNPO is a key enzyme in vitamin B6 coenzyme metabolism and is highly expressed in MM. Increased PNPO levels correlate with disease progression by promoting cell proliferation and inducing osteoclast differentiation through exosomes.",{"name":70,"@type":61,"acceptedAnswer":71},"How was hetrombopag identified and what did it do in preclinical and early clinical data?",{"text":72,"@type":64},"Hetrombopag was identified through structure-based virtual screening targeting critical PNPO residues (R95 and K117). It inhibited MM cell proliferation and osteoclast differentiation, and preliminary clinical data supported prolonged survival in MM patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352650,1790359198,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Basic & Clinical Pharmacology & Toxicology   \n ORIGINAL ARTICLE  OPEN ACCESS   \nRepurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol-Inspired Approach  \nTianyi Yu1,2 | Cheng Wang2 | Jingru Xie2 | Yongxin Wei2 | Hongwei Cui3 | Huaxia Zhang2 | Fan Zhou4 | Zhendong Deng2 | Ye Yang2 | Chunyan Gu1,2   \n1Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China | 2School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China | 3School of Elderly Care Services and Management, Nanjing University of Chinese Medicine, Nanjing, China | 4Department of Hematology and Oncology, Jing'an District Zhabei Central Hospital, Shanghai, China  \nCorrespondence: Fan Zhou ([zfsh257@163.com](zfsh257@163.com)) | Zhendong Deng ([dengzhendong@njucm.edu.cn](dengzhendong@njucm.edu.cn)) | Ye Yang ([yangye876@sina.com](yangye876@sina.com)) | Chunyan Gu ([guchunyan@njucm.edu.cn](guchunyan@njucm.edu.cn))  \nReceived: 20 January 2026 | Revised: 26 February 2026 | Accepted: 9 March 2026  \nKeywords: hetrombopag | multiple myeloma | oxidation | pyridoxine-5′-phosphate oxidase | reactive oxygen species  \nABSTRACT  \nMultiple myeloma (MM) is a malignancy of plasma cells whose excessive immunoglobulin production elevates reactive oxygen species (ROS), promoting pathogenesis. Active compounds from Traditional Chinese Medicine, such as celastrol, can exert antitumour effects by further increasing ROS levels to toxic levels, thereby inducing apoptosis. Our previous study has demonstrated that pyridoxine-5′-phosphate oxidase (PNPO) is the specific target of celastrol. In this study, we discovered that PNPO, a key enzyme involved in vitamin B6 coenzyme metabolism, is highly expressed in various cancers, including MM. Increased PNPO levels correlated with MM disease progression, promoting cell proliferation and inducing osteoclast differentiation via exosomes. Concurrently, through a structure-based virtual screening workflow targeting critical PNPO residues (R95 and K117), we identified Hetrombopag as a potential PNPO inhibitor. Hetrombopag simultaneously inhibited MM cell proliferation and osteoclast differentiation. Preliminary data from clinical trials also supported the idea that hetrombopag treatment can prolong survival in MM patients. Our research highlights the significant role of PNPO in MM progression and suggests hetrombopag as a promising therapeutic option for MM treatment.  \n1 | Introduction  \nMultiple myeloma (MM) is a type of blood cancer that arises from the abnormal proliferation of monoclonal plasma cells, which is characterized by a predisposition to bone lesions, hypercalcaemia, anaemia and numerous other complications [1, 2] . The release of large immunoglobulins from plasma cells generates excessive levels of reactive oxygen species (ROS) in MM cells [3], which are then exacerbated by excessive cancer cell metabolism [4] . An iron-rich microenvironment in MM,  \ndriven by pro-inflammatory cells, provides an additional catalyst for ROS production [5] . Excessive levels of ROS activate the PI3K and MAPK signalling pathways, thereby accelerating MM cell proliferation [6] . Concurrently, ROS upregulates RANKL, a critical mediator of osteoclast differentiation and function, directly contributing to osteolytic bone damage [7], which diminishes MM patient survival. ROS also activates nuclear respiratory factors (NRF), leading to the transcriptional upregulation of antioxidant enzymes, including superoxide dismutase (SOD) and catalase (CAT) [8–10] . Consequently,  \n\n| Tianyi Yu and Cheng Wang have contributed equally to this work.\u003Cbr>BCPT recognizes the potential of natural product studies in the identification of new therapies but wishes to emphasize that findings based on uncharacterized mixtures of compounds are preliminary in nature and serve primarily as hypothesis-generating to form the basis for more elaborate investigations. |\n| --- |\n| This is an open access article und","cbCaiuQtXAFKOfAi","https://ap.wps.com/l/cbCaiuQtXAFKOfAi","pdf",2445262,12,"English","# Introduction\n## Multiple myeloma, ROS, and signalling pathways\n## PNPO as a therapeutic target\n## Celastrol-inspired PNPO inhibition\n## Hetrombopag effects and preliminary clinical support","[{\"question\":\"Why is ROS elevated in multiple myeloma cells, and how does it affect disease progression?\",\"answer\":\"MM plasma cells produce excessive immunoglobulins that raise ROS. The elevated ROS further accelerates proliferation through PI3K/MAPK signalling and promotes osteoclast differentiation via RANKL, contributing to bone damage and reduced survival.\"},{\"question\":\"What role does PNPO play in MM according to the study?\",\"answer\":\"PNPO is a key enzyme in vitamin B6 coenzyme metabolism and is highly expressed in MM. Increased PNPO levels correlate with disease progression by promoting cell proliferation and inducing osteoclast differentiation through exosomes.\"},{\"question\":\"How was hetrombopag identified and what did it do in preclinical and early clinical data?\",\"answer\":\"Hetrombopag was identified through structure-based virtual screening targeting critical PNPO residues (R95 and K117). It inhibited MM cell proliferation and osteoclast differentiation, and preliminary clinical data supported prolonged survival in MM patients.\"}]","Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO - A Celastrol-Inspired Approach | PDF",1790100636,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f1d25ff5bd574adca8b46e94e2305aa.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f51238af811c34f37c78ee0f7e9a235.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b3183c590ce933460f22d3f870eecf7.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94cdf1c1ccbeea1d017b8a8f33ec4412.webp",980,1287]